Heuft H G, Goudeva L, Blasczyk R
Department of Transfusion Medicine, Hannover Medical School, Carl Neuberg Strasse 1, 30623, Hannover, Germany.
Ann Hematol. 2004 May;83(5):279-85. doi: 10.1007/s00277-003-0816-9. Epub 2003 Nov 27.
Both granulocyte colony-stimulating factor (G-CSF) and dexamethasone (DXM) are used for neutrophil (PMN) mobilization and collection. This prospective study was aimed to evaluate and compare the rate, severity and clinical significance of adverse reactions of these drugs alone and in combination in healthy donors. PMN mobilization was carried out using dexamethasone alone (8 mg orally; n=25) or glycosylated G-CSF alone (Lenograstim, 5 microg/kg subcutaneously, n=24) or in combination (n=23) prior to a standard granulocyte apheresis on the Spectra cell separator. The number of PMNs counted in the mobilized peripheral blood of the donors was 7.0 (3.6-20.4) x10(9)/L (DXM), 25.2 (15.5-49.7) x10(9)/L (G-CSF), and 31.6 (20.0-43.0) x10(9)/L (G-CSF+DXM), corresponding to PMN apheresis yields of 13 (8-43) x10(9)/U, 56 (34-118) x10(9)/U, and 83 (33-117) x10(9)/U, respectively. The three groups had comparable percentages of donors with at least one adverse effect (ranging from 75 to 80%), but the G-CSF-containing regimens were generally more toxic, as was reflected by higher percentages of donors with moderate to severe adverse reactions and higher overall severity scores of 2.28 (G-CSF) and 2.08 (G-CSF+DXM) compared with 1.33 in the DXM group ( p<or=0.001). With G-CSF alone, pain symptom complexes were more frequent, more severe, and more often triggered requests for analgesics (9/47 donors; 19%) and unwillingness to give further neutrophil donations (2/47 donors; 4%). The addition of DXM to G-CSF diminished some symptoms, particularly bone pain, headache and the frequency of requests for analgesics. The predominant symptoms in the DXM alone group were mild gastrointestinal complaints. We conclude that G-CSF stimulation improved neutrophil mobilization and apheresis yields at the expense of donor tolerability. Compared with G-CSF alone, the combination G-CSF and DXM did not increase the quantity or the severity of donor symptoms.
粒细胞集落刺激因子(G-CSF)和地塞米松(DXM)都用于中性粒细胞(PMN)的动员和采集。这项前瞻性研究旨在评估和比较这些药物单独使用及联合使用时在健康供者中不良反应的发生率、严重程度及临床意义。在使用Spectra血细胞分离机进行标准粒细胞单采术前,分别单独使用地塞米松(口服8毫克;n = 25)、单独使用糖基化G-CSF(非格司亭,皮下注射5微克/千克,n = 24)或联合使用(n = 23)来进行PMN动员。供者动员外周血中PMN计数分别为7.0(3.6 - 20.4)×10⁹/L(DXM组)、25.2(15.5 - 49.7)×10⁹/L(G-CSF组)和31.6(20.0 - 43.0)×10⁹/L(G-CSF + DXM组),对应的PMN单采产量分别为13(8 - 43)×10⁹/U、56(34 - 118)×10⁹/U和83(33 - 117)×10⁹/U。三组中至少出现一种不良反应的供者百分比相当(75%至80%),但含G-CSF的方案总体毒性更大,这体现在中度至重度不良反应供者的百分比更高,以及总体严重程度评分更高,G-CSF组为2.28,G-CSF + DXM组为2.08,而DXM组为1.33(p≤0.001)。单独使用G-CSF时,疼痛症状复合体更频繁、更严重,更常引发使用镇痛药的需求(9/47名供者;19%)以及不愿再进行中性粒细胞捐献(2/47名供者;4%)。在G-CSF中加入DXM可减轻一些症状,尤其是骨痛、头痛以及使用镇痛药的频率。单独使用DXM组的主要症状为轻度胃肠道不适。我们得出结论,G-CSF刺激提高了中性粒细胞动员和单采产量,但以供者耐受性为代价。与单独使用G-CSF相比,G-CSF与DXM联合使用并未增加供者症状的数量或严重程度。